Patanjali asks Madras HC to vacate stay on use of ‘Coronil’

A week after the Madras high court restrained Patanjali Ayurveda from using the trademark ‘Coronil’ for its controversial ‘Covid-19 cure’, the company has moved the court seeking to vacate the stay.

Patanjali claimed that the trademark infringement suit is part of a larger conspiracy to scuttle its business. When the plea came up for hearing before Justice C V Karthikeyan on Friday, the company requested the court to pass a gag order restraining the media from reporting the case.

Refusing to grant any such interim relief, the judge adjourned the hearing to July 27.
According to the company, if the injunction order is not vacated, people of the country would not be able to take advantage of the ‘immunity booster tablets’ formulated with huge investments.

It further contended that the original manufacturer of the drug is Divya Yog Mandir Trust and Patanjali is only marketing it.
Claiming that it started marketing the drug only after making an appropriate application for registering trademark ‘Coronil’ with the trademarks registry, the company said it is a common practice in the pharmaceutical industry to name a drug after an ailment, organ or medical compound.

The class of customers, market and mode of purchase of goods were completely different compared to that of Arudra Engineering Private Limited which has claimed that ‘Coronil’ is a trademark owned by it since 1993, the company added that the suit is not maintainable on any grounds.

Source Link